Search

Interferon beta-1b

Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

Lomitapide

[A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … [A275444, A7367] It was developed to address the significant unmet medical need in patients with homozygous familial hypercholesterolemia (HoFH)—an ultra-rare and life-threatening genetic disorder characterized

Letermovir

[A31290] Letermovir has recieved both priority and orphan drug status from the FDA. It is currently marketed under the brand name Prevymis.[L1021]

Rubidium

Almasilate

Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].

DL-dimyristoylphosphatidylcholine

A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial drug preparations to solubilize drugs for injection

Plozasiran

[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]

Uridine triacetate

As a result, these metabolites are associated with various unpleasant side effects such as neutropenia, mucositis, diarrhea, and hand–foot syndrome. … It is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself.

Aminoglutethimide

Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties.

Tebentafusp

[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic T cells to lyse the cells, such as melanocytes.